Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in Hidradenitis Suppurativa
NCT05040698Phase 2Completed
- Sponsor
- Holdsworth House Medical Practice
- Start
- Oct 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fostamatinib in hidradenitis suppurativa (HS), sponsored by Holdsworth House Medical Practice. Started Oct 2021; status: completed.
02
Drugs
fostamatinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05040698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040698.